Authors
Pederson, ThoruUMass Chan Affiliations
Department of Biochemistry and Molecular PharmacologyDocument Type
EditorialPublication Date
2021-09-06Keywords
Immunology and Infectious DiseaseInfectious Disease
Microbiology
Technology and Innovation
Virus Diseases
Metadata
Show full item recordAbstract
Many pandemic issues have been swirling around in our country, and most have received extensive media coverage, most notably vaccine hesitancy/resistance, the Delta variant, and the continuing extreme importance of masking. Another is the collective angst over the time it is taking the FDA to issue full approvals of the earliest vaccines to apply for it. (It is anticipated that at least one vaccine will have received this by the time this editorial appears.) In the background, not exactly sotto voce but receiving less print, is the question of whether the US government might exercise its so-called march-in authority on the relevant patents. Its statutory footing and operative domain are often misunderstood, and here I seek to clarify this for our readers. I am motivated to do so because I did not initially understand it either.Source
Pederson T. US companies' COVID patents: Will "the saints go marching in"? FASEB J. 2021 Oct;35(10):e21879. doi: 10.1096/fj.202101282. PMID: 34486747. Link to article on publisher's site
DOI
10.1096/fj.202101282Permanent Link to this Item
http://hdl.handle.net/20.500.14038/27553PubMed ID
34486747Related Resources
ae974a485f413a2113503eed53cd6c53
10.1096/fj.202101282